

Al-Mustaqbal University College
Department of Pharmacy
General Toxicology
4th stage
Lecture: 7




Cardiac Toxicology

QASSIM A ZIGAM

Toxicological Cardiomyopathy

- ✓ Many substances can cause cardiac toxic responses **directly** or **indirectly**.
- ✓ However, **only** chemicals that **primarily** act on the heart be categorized as **cardiac toxic chemicals**.
- ✓ **Clinically**, the most recognized toxicological cardiomyopathy is found in alcoholic heart muscle disease, which is often referred to as **alcoholic cardiomyopathy** (ACM).



Biomarkers for CVS Injury

CARDIAC MARKERS	BACKGROUND	USE
Creatine kinase	Elevation of specific isoform CK-MB in the serum is a specific marker of acute myocardial infarction	Routinely used clinical and preclinical myocardial injury marker
Myoglobin	Elevation of serum myoglobin is likely reflective of the extent of myocardial damage, although not specific to cardiac muscle	Readily available clinical and preclinical marker, although lack of specificity has led to reduced utilization
B-type natriuretic peptide	Cardiac neurohormone secreted by the ventricular myocardium in response to volume and pressure overload, and the release of BNP is a valuable indicator of heart failure	BNP is an important diagnostic marker as well as a drug used to alleviate congestive heart failure symptoms in cardiac decompensation. BNP has value for preclinical models of heart failure across species
Cardiac troponins	Cardiac troponin T (cTnT) and I (cTnI) are constituents of the myofilaments and expressed exclusively in cardiomyocytes. It is thus of absolute myocardial tissue specificity	“Gold Standard” for diagnosis of myocardial infarction. Value extends to preclinical safety and experimental models

Cardiac Toxic Chemicals

The chemicals that cause cardiac toxicity can be categorized into

1. Pharmaceutical agents


2. Natural products

3. Environmental chemicals

4. Industrial chemicals

Pharmaceutical Agents

- ✓ Cardiac toxicity of pharmaceutical chemicals is a **major problem** in drug **development** and their **clinical** application.
- ✓ These chemicals can be simply **classified** as drugs used to treat **cardiac** disease and others used to treat **noncardiac** disease.




Pharmaceutical Chemicals

- ✓ Cardiac drugs can cause cardiotoxicity that is either related or not related to **their therapeutic action**.
- ✓ Drugs such as **digitalis, quinidine, and procainamide** often cause acute **arrhythmia**, which is **reversible** upon cessation of their use.
- ✓ While **catecholamines** may cause cardiac toxicity through **oxidative stress**, rather than by their action on the sympathetic nervous system.

Pharmaceutical Chemicals

- ✓ The cardiotoxicity of **noncardiac** drugs limits their uses.
- ✓ For instance, the anticancer **Adriamycin**, can produce severe cardiac toxicity that limits its use.
- ✓ **Rofecoxib** is a selective COX-2 inhibitor used as an anti-inflammatory drug, but it causes **QT prolongation** and increases the risk for **sudden cardiac death**.




Antiarrhythmic Agents

- ✓ Antiarrhythmic drugs have historically been **classified** based upon a primary **mechanism of action**:
 1. Na⁺ channel blockers (class I)
 2. β-adrenergic blockers (class II)
 3. K⁺ channel blockers (class III)
 4. Ca²⁺ channel blockers (class IV).
- ✓ However, this classification is **artificial** because most drugs have **multiple** mechanisms of action.

Class I Antiarrhythmic Agents

- ✓ These are primarily Na^+ channel blockers, such as disopyramide, flecainide, lidocaine, mexiletine, procainamide, and quinidine.
- ✓ **Blockade** of cardiac Na^+ channels results in a **reduction** of conduction velocity, **prolonged** QRS duration, and **decreased** automaticity.



Class I Antiarrhythmic Agents

✓ The primary concern of Na⁺ channel blocker toxicity is that **proarrhythmic** effects are seen at a much higher incidence in those patients with:

1. Previous history of myocardial infarction
2. Acute myocardial ischemia
3. Other cardiac complications

Class II Antiarrhythmic Drugs

- ✓ These are **β -adrenergic receptor-blocking** drugs, including acebutolol, esmolol, propranolol, and sotalol.
- ✓ These drugs lead to opposite effects to that of catecholamines and are useful for the treatment of **supraventricular tachycardia**.
- ✓ The main adverse cardiovascular effect of β -adrenergic receptor antagonists is **hypotension**.
- ✓ These drugs may also exacerbate **AV conduction deficits** (e.g., heart block) and promote **arrhythmias**.

Class III Antiarrhythmic Drugs

- ✓ These are primarily K⁺ channel blockers including amiodarone, bretylium, dofetilide, ibutilide, quinidine, and sotalol.
- ✓ Blockade of K⁺ channels **increases** action potential duration and **increases** refractoriness.
- ✓ The most noticeable adverse effect of these drugs is **QT prolongation** and **torsadogenesis**.
- ✓ Amiodarone and quinidine also block Na⁺ channels, whereas sotalol inhibits β-adrenergic receptors in the heart.


Class III Antiarrhythmic Drugs

- ✓ **Amiodarone** **prolongs** action potential **duration** and effective **refractory** period of Purkinje fibres and ventricular myocytes the most common adverse cardiovascular effect of amiodarone is **bradycardia**.
- ✓ Amiodarone may also have cardiotoxic effects by **stimulating** excessive **Calcium uptake**, especially in the presence of **procaine**.



Class IV Antiarrhythmic Drugs

- ✓ These are Ca^{2+} channel blockers and include **bepridil**, **diltiazem** and **verapamil**.
- ✓ These drugs exert **negative** inotropic and chronotropic effects thus they may produce **bradycardia**.
- ✓ In contrast, the **dihydropyridine** Ca^{2+} channel blockers such as amlodipine, felodipine and nicardipine typically induce a **reflex tachycardia**.



Inotropic Drugs

✓ **Drugs involved in this category include:**

- 1. The cardiac glycosides**
- 2. Ca²⁺ sensitizing agents**
- 3. Catecholamines**
- 4. Other sympathomimetic drugs**

✓ **Inotropic drugs** may exert **cardiotoxic** effects through extensions of their **pharmacological action**.

Cardiac Glycosides

- ✓ These (digoxin and digitoxin) are inotropic drugs used for the treatment of **congestive heart failure**.
- ✓ The mechanism of inotropic action of cardiac glycosides involves **inhibition of Na⁺/K⁺ ATPase**.
- ✓ Consequently, cardiotoxicity may result from **calcium overload**, potentially including a reduction in resting membrane potential (less negative), and **premature ventricular contraction** or **ectopic** beats.

Cardiac Glycosides

✓ The principal adverse cardiac effects of cardiac glycosides include:

1. **Slowed** AV conduction with potential block

2. **Ectopic** beats

3. **Bradycardia.**

✓ During an **overdose**, when the resting membrane potential is significantly altered, and **ectopic beats** are prevalent, ventricular **tachycardia** may develop and can progress to **ventricular fibrillation.**

Ca²⁺-Sensitizing Drugs


- ✓ Calcium sensitizing drugs, including adibendan, levosimendan, and pimobendane, are useful as **inotropic** drugs for the treatment of **heart failure**.
- ✓ In **contrast** to the main mechanism by which many other inotropic drugs act through elevating **intracellular-free Ca²⁺**, these drugs increase the Ca²⁺ **sensitivity** of cardiac myocytes, thereby **avoiding Ca²⁺ overload**.

Ca²⁺-Sensitizing Drugs

- ✓ The possibility that such Ca²⁺sensitizing drugs interfere with **diastolic function (relaxation)** and may contribute to **ventricular** arrhythmias.
- ✓ Other Ca²⁺sensitizing drugs include the xanthine oxidase inhibitors allopurinol and oxypurinol, which have been shown to **increase** the contractile force but **decrease** Ca²⁺ transient amplitude.

Catecholamines

- ✓ These neurotransmitters exert a **wide range** of cardiovascular effects because of their ability to activate **α - and β -adrenergic receptors**.
- ✓ A number of **synthetic** catecholamines have been developed for the treatment of **cardiovascular** disorders and other conditions such as **asthma** and **nasal congestion**.



Catecholamines

- ✓ **Inotropic** and **chronotropic** catecholamines used to treat **bradycardia**, or cardiac **decompensation** following surgery include epinephrine, isoproterenol, and dobutamine.
- ✓ More **selective β 2-adrenergic** receptor agonists used for **bronchodilatory** effects in asthma include albuterol, formoterol, salmeterol, and terbutaline.

Catecholamines

- ✓ **High circulating concentrations** of catecholamine may cause **cardiac myocyte death**.
- ✓ Many of the catecholamines and related drugs have been shown to induce **cardiac myocyte hypertrophic growth in vitro**.
- ✓ **Catecholamine-induced cardiotoxicity** involves increased heart rate, enhanced myocardial oxygen demand, and an overall increase in systolic arterial blood pressure.

CNS Acting Drugs

✓ Some of the central nervous system (CNS)–acting drugs have **considerable** effects on the cardiovascular system, including:

1. Tricyclic antidepressant (TCAs)
2. General anaesthetics
3. Opioids
4. Antipsychotic drugs

Tricyclic Antidepressants

- ✓ TCAs including amitriptyline, doxepin, imipramine, and protriptyline have **significant cardiotoxic** effects, particularly in cases of **overdose**.
- ✓ The effects of TCAs **on the heart include ST-segment elevation, QT prolongation, SVT and VT, and sudden cardiac death.**
- ✓ In addition, as a result of the peripheral **α -adrenergic blockade**, TCAs cause **postural hypotension**.

Tricyclic Antidepressants

- ✓ Although many of these adverse effects are related to the **quinidine-like** actions, **anticholinergic** effects, and **adrenergic** actions of these drugs.
- ✓ The tricyclics also have **direct actions** on cardiac myocytes and Purkinje fibers, including **depression** of **inward** Na^+ and Ca^{2+} and **outward** K^+ currents.

Antipsychotic Drugs

- ✓ As with TCAs, the most prominent adverse cardiovascular effect of antipsychotic drugs is **orthostatic hypotension**.
- ✓ However, the **phenothiazines** (e.g., chlorpromazine and thioridazine) may exert **direct** effects on the myocardium, including **negative inotropic** actions and **quinidine-like** effects.
- ✓ Some ECG changes induced by these drugs include **prolongation of the QT and PR intervals** and **depression** of the ST segment.
- ✓ Through **anticholinergic** actions, **clozapine** can produce substantial elevations in heart rate (**tachycardia**).

General Anesthetics

- ✓ General anaesthetics as exemplified by desflurane, halothane, isoflurane, and methoxyflurane.
- ✓ They have adverse cardiac effects, including **reduced cardiac output** by 20% to 50%, **depression of contractility**, and **production of arrhythmias.**
- ✓ These anaesthetics may **sensitize** the heart to the **arrhythmogenic** effects of **endogenous** epinephrine or to β -receptor agonists.

General Anesthetics

- ✓ **Halothane** has been found to
1. **Block the L-type Ca^{2+} channel and modify the responsiveness of the contractile proteins to activation by Ca^{2+} .**
 2. **Decreases cardiac output and blood pressure.**
 3. **Causes a negative inotropic effect by its direct action on cardiac myocytes.**
 4. **Antagonize β -adrenergic receptors.**



Anti-inflammatory Agents

- ✓ **NSAIDs** include aspirin, Ibuprofen, and Diclofenac, they are classified as **nonselective** NSAIDs because they are inhibitors for both **COX-1 and COX-2**.
- ✓ Inhibition of **COX-1** is associated with **GI toxicity** because COX-1 exerts a protective effect on the lining of the stomach.
- ✓ NSAIDs have been developed including rofecoxib, celecoxib, and valdecoxib, which are **selective inhibitors of COX-2**.

Anti-inflammatory Agents

- ✓ The **cardiovascular** events induced by COX-2 inhibitors are presumably related to **thrombotic events** and other sequelae related to the **downregulation of prostacyclin production**.
- ✓ Studies have also indicated the link of rofecoxib to **long QT syndrome** and the increased **risk for Torsades** and **sudden cardiac death**.

Aminoglycosides

- ✓ These include amikacin, gentamicin, kanamycin, netilmicin, streptomycin, and tobramycin.
- ✓ Aminoglycosides **inhibit** the uptake or binding of Ca^{2+} at **sarcolemmal sites**, thus **reducing** the concentration of membrane-bound Ca^{2+} available for **movement** into the myoplasm during **depolarization** of the sarcolemma.
- ✓ **Gentamicin** is a representative aminoglycoside and has an **inhibitory** action on slow **inward Ca^{2+} channels** in heart muscle.

Macrolides

- ✓ These include azithromycin, clarithromycin, dirithromycin, and erythromycin.
- ✓ **Erythromycin** is associated with **QT prolongation** and cardiac **dysrhythmias** that is characterized by **polymorphic** ventricular tachycardia (Torsades).
- ✓ These effects occur **primarily** in patients with **underlying cardiac disease**.



Fluoroquinolones

- ✓ Grepafloxacin, moxifloxacin, and sparfloxacin are associated with **QT prolongation** in perhaps a **higher** incidence than **macrolides**.
- ✓ **Grepafloxacin** was **removed** from the U.S. market because of the relatively high incidence of **QT prolongation** and the risk of **Torsades de Pointes**.



Antifungal Agents

- ✓ Antifungal agents, such as **amphotericin B**, may **depress myocardial contractility** by blocking the activation of slow Ca^{2+} channels and inhibiting the influx of Na^+ .
- ✓ **Ventricular tachycardia** and **cardiac arrest** have been reported in patients treated with amphotericin B.

Antifungal Agents

- ✓ **Flucytosine** is another antifungal drug that has been associated with **cardiotoxicity**.
- ✓ However, flucytosine may be converted to **5-fluorouracil** by gastrointestinal microflora in humans, which then may be **absorbed** systemically and induce **cardiotoxicity**.
- ✓ **Cardiac arrest** has been reported in individuals receiving flucytosine.

NDC 68682-355-10 *Rx Only*
**Flucytosine
Capsules**



**THANK YOU
FOR YOUR ATTENTION**